Mazdutide (IBI362) is a dual GLP-1 and glucagon receptor co-agonist evaluated in Phase 2 and Phase 3 clinical trials. This evidence review examines publish
Read more Mazdutide Clinical Trials: Human Evidence, Efficacy, and Metabolic Outcomes
Mazdutide Clinical Trials: Human Evidence, Efficacy, and Metabolic Outcomes